BioTricity Inc. Files Annual Report Amendment

Ticker: BTCY · Form: 10-K/A · Filed: Jun 28, 2024 · CIK: 1630113

Sentiment: neutral

Topics: amendment, annual-report, medical-devices

TL;DR

BioTricity filed its 2024 10-K amendment. Check financials.

AI Summary

BioTricity Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended March 31, 2024. The company, formerly known as MetaSolutions, Inc., is incorporated in Nevada and operates in the surgical and medical instruments sector. Its principal executive offices are located in Redwood City, California.

Why It Matters

This filing provides updated information for the fiscal year 2024, which is crucial for investors to assess the company's financial health and operational status.

Risk Assessment

Risk Level: medium — As a 10-K/A filing, it indicates potential corrections or additions to the original annual report, which could signal underlying issues or complexities in the company's financial reporting.

Key Numbers

Key Players & Entities

FAQ

What specific changes or additions are detailed in this 10-K/A amendment?

The filing is an amendment to the annual report for the fiscal year ended March 31, 2024, indicating that the original filing may have contained errors or omissions that are now being corrected or supplemented.

What is the primary business of BioTricity Inc.?

BioTricity Inc. is involved in the 'SURGICAL & MEDICAL INSTRUMENTS & APPARATUS' industry, as indicated by its SIC code 3841.

When did BioTricity Inc. change its name from MetaSolutions, Inc.?

The company changed its name from MetaSolutions, Inc. on January 7, 2015.

Where are BioTricity Inc.'s principal executive offices located?

The principal executive offices are located at 203 Redwood Shores Parkway, Suite 600, Redwood City, CA 94065.

What is the significance of the filing date and the date as of change?

The filing was made on June 28, 2024, with a date as of change of June 27, 2024, indicating the most recent date for which information in the filing is considered current.

Filing Stats: 2,697 words · 11 min read · ~9 pages · Grade level 9.4 · Accepted 2024-06-27 19:55:56

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Section 13 or 15 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on the day of June 27, 2024. BIOTRICITY INC. By: /s/ Waqaas Al-Siddiq Waqaas Al-Siddiq Chief Executive Officer and President In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. Signature Title Date /s/ Waqaas Al-Siddiq Chairman, President and Chief Executive Officer (principal executive officer) June 27, 2024 Waqaas Al-Siddiq /s/ John Ayanoglou Chief Financial Officer (principal financial and accounting officer) June 27, 2024 John Ayanoglou /s/ David A. Rosa Director June 27, 2024 David A. Rosa /s/ Chester White Director June 27, 2024 Chester White /s/ Ronald McClurg Director June 27, 2024 Ronald McClurg 4

View Full Filing

View this 10-K/A filing on SEC EDGAR

View on Read The Filing